The abstract is read at the publisher; the summary is JClub's.
Lipid nanoparticle platforms can be programmed across molecular, tissue, systemic, and organismal scales to direct immune responses for cancer therapy, including in vivo CAR-T engineering and vaccine-driven memory.
- Why it matters: Cancer immunotherapy is constrained by off-target toxicity, solid-tumor physical barriers, and the manufacturing complexity of personalized cell therapies.
- What they did: The review outlines multi-scale systemic immune programming where LNP design and intracellular delivery tune mRNA stability, translation, and antigen presentation, while tissue and systemic delivery reprogram the tumor microenvironment and enable in vivo CAR-T engineering and immune memory.
- The result: The framework proposes a dual-track paradigm combining tumor-directed immune activation with host physiological restoration, positioning LNP-based treatments to address cancer as a systemic immunometabolic disorder rather than a localized one.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.